Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta can interact with ...

Innoviva is focused on critical care and infectious disease therapeutics, with revenue from GSK royalties and recent acquisitions bolstering its portfolio. The company faces challenges in its product ...

Anoro Ellipta side effects Anoro Ellipta can cause mild or serious side effects. The following lists contain some of the key side effects that may occur while taking Anoro Ellipta. These lists do not ...

Anoro Ellipta is a brand-name inhaler that’s prescribed for long-term chronic obstructive pulmonary disease (COPD) treatment. Anoro Ellipta contains the active ingredients vilanterol and umeclidinium.

GSK plc GSK announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rivals AstraZeneca AZN and Boehringer ...

On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...

Anoro Ellipta is a brand-name prescription medication to manage chronic obstructive pulmonary disease (COPD) symptoms in adults. Common side effects of Anoro Ellipta are generally mild, but serious ...

Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's financials have shown improvement, with increased ...

Please provide your email address to receive an email when new articles are posted on . Outcomes may vary among different fixed-dose combination inhalers for COPD ...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the fourth quarter and the year ended December 31, 2021. Pavel ...

GSK sells 32% stake in product portfolio company Innoviva was separated from Theravance in 2014 GSK says royalty agreements with Innoviva unchanged The London-listed company sold its stake of about 32 ...

Please provide your email address to receive an email when new articles are posted on . The FDA Pulmonary-Allergy Drugs Advisory Committee voted 14-1 against a proposed labeling claim that Trelegy ...